Studies to date have not determined whether GO, besides acting on the more mature CD33+ progeny, can indeed directly kill CD33+ LSCs in vivo, and whether long-term benefit from GO is related to successful targeting of LSCs, including AML cases that harbor CD33− LSCs. Here, CD33 is linked to acute myeloid leukemia.